INmune Bio is taking its investigational cell therapy Ebstrocel™ global. The biotech has signed a Master Services Agreement with Uniphar to support international distribution and named-patient access for Ebstrocel™ — a stromal cell therapy targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB) — starting with select European and MENA countries. The deal gives INmune Bio a capital-efficient path to reach patients before full regulatory approval.
INmune Bio has inked a Master Services Agreement with Uniphar Durbin Ireland Limited to build a scalable international commercialization framework for Ebstrocel™ (pobistrocel), its investigational allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) — a rare and severe genetic skin disorder. The partnership kicks off with named-patient access in select European countries and the Middle East and North Africa (MENA), with potential to expand further as regulatory approvals are secured.
Rather than building country-by-country infrastructure from scratch, INmune Bio is leveraging Uniphar's established global platform — covering regulatory feasibility, market access, product storage, distribution, pharmacovigilance, and end-to-end shipment tracking. The company says this approach is both capital-efficient and strategically sound for reaching patients ahead of broad commercial availability.
Key Takeaways:
Why it matters: For patients with RDEB — a debilitating condition with very limited treatment options — this agreement could open a critical early access pathway internationally, while laying the commercial groundwork for broader availability down the line.
